Design of binder proteins specific to IL-13.

Area of Science:

• Biochemistry
• Immunology
• Computational Biology

Background:

• Interleukin-13 (IL-13) is a key driver of type 2 inflammatory disorders.
• Current anti-IL-13 therapies (e.g., monoclonal antibodies) face limitations due to their large size for topical applications.
• Developing smaller, targeted IL-13 inhibitors is crucial for advancing topical immunotherapy.

Purpose of the Study:

• To computationally design and develop novel, compact minibinder proteins targeting IL-13.
• To assess the binding affinity, inhibitory potential, and functional efficacy of these minibinders.
• To explore the potential of these minibinders for topical immunotherapy.

Main Methods:

• Structure-based computational design utilizing the IL-13-tralokinumab complex crystal structure.
• Expression and biophysical characterization of designed minibinder constructs.
• In vitro functional assays including TF-1 cell proliferation inhibition, STAT6 phosphorylation suppression, and pro-inflammatory gene expression analysis in A549 cells.

Main Results:

• Five minibinder constructs were successfully designed, expressed, and characterized.
• Binder1 demonstrated the strongest binding affinity (nanomolar range) and potent IL-13 antagonism (IC50 = 56.39 nM).
• Binder1 effectively inhibited IL-13-dependent cell proliferation, suppressed STAT6 phosphorylation, and attenuated pro-inflammatory gene expression.

Conclusions:

• Minimalistic, potent IL-13-targeting minibinders were successfully designed using computational methods.
• Binder1 exhibits significant potential as a therapeutic agent for IL-13-related inflammatory conditions.
• These minibinders offer a promising avenue for the development of novel topical immunotherapies.